Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXEL: Nivolumab +/- Capecitabine in TNBC
NCT03487666Phase 2Completed
- Sponsor
- Georgetown University
- Start
- May 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in triple-negative breast cancer (TNBC), sponsored by Georgetown University. Started May 2018; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03487666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487666.